Skip to main content

Table 1 Different types of mTORC2 targeted drugs

From: The role of RICTOR amplification in targeted therapy and drug resistance

Drug typeNameTumor or cell lineReference
ATP-competitive mTOR inhibitorCZ415Head and neck squamous cell carcinoma (HNSCC), papillary thyroid carcinoma(Xie et al. 2018; Li et al. 2018)
Torin2Adult T-cell leukemia/lymphoma, anaplastic thyroid cancer(Watanabe et al. 2016; Sadowski et al. 2015)
MLN0128
(INK128)
Intrahepatic cholangiocarcinoma
Neuroblastoma, breast cancer, osteosarcoma
(Zhang et al. 2017; Zhang et al. 2015; Liu et al. 2016)
PP242Glioblastoma, ovarian cancer(Mecca et al. 2018; Kawata et al. 2018; Musa et al. 2016)
AZD8055Adult T-cell leukemia (ATL), hepatocellular carcinoma, colon cancer, neuroblastoma(Kawata et al. 2018; Chen et al. 2018; Xu et al. 2018)
AZD2014Diffuse intrinsic pontine glioma (DIPG), gastric cancer, anaplastic thyroid carcinoma (ATC), ovarian cancer(Kim et al. 2017a; Milosevic et al. 2018; Wong Te Fong et al. 2017; Flannery et al. 2018)
PI3K/mTOR inhibitorDactolisib
(BEZ235)
Colon cancer, glioblastomas, breast cancer(Yu et al. 2016; Shi et al. 2018; Torki et al. 2017)
GSK1059615Head and neck squamous cell carcinoma (HNSCC)(Xie et al. 2017a)
LY3023414Esophageal Adenocarcinoma(Zaidi et al. 2017)
voxtalisib
(SAR245409, XL765)
endometrial carcinoma(Yu et al. 2014; Inaba et al. 2015)
PQR309brain tumor or CNS metastasis(Beaufils et al. 2017)
gedatolisib (PKI-587, PF05212384)breast, colon, lung, and glioma carcinoma(Venkatesan et al. 2010)
omipalisib (GSK2126458)breast carcinoma(Knight et al. 2010)
mTORC1/2 dual inhibitorCC-223Hepatocellular carcinoma, colorectal cancer, head and neck squamous cell carcinoma (HNSCC)(Xie et al. 2017b; Wang et al. 2018a)
Ku0063794Hepatocellular carcinoma(Kim et al. 2017b)
OSI027Pancreatic cancer, colon cancer(Chen et al. 2015; Bhagwat et al. 2011; Zhi et al. 2015)
RES-529 (Palomid 529)Osteosarcoma, angiogenesis and vascular permeability, prostate cancer(Hu et al. 2018; Xue et al. 2008; Gravina et al. 2011)
WYE-687Renal carcinoma, acute myeloid leukemia (AML)(Pan et al. 2017; Cheng et al. 2016)
WYE-354Colon cancer, gallbladder cancer(Wang et al. 2016; Weber et al. 2015)